2.Surgery for Presbyopia.
Journal of the Korean Medical Association 2001;44(4):392-402
No abstract available.
Presbyopia*
3.Surgeon's View of Chemotherapy in Gastric Cancer.
Journal of the Korean Gastric Cancer Association 2003;3(4):166-171
No abstract available.
Drug Therapy*
;
Stomach Neoplasms*
4.Clinical review of vreast cancer.
Byung Kwang MIN ; Il Myung KIM ; Byung Ook YOU
Journal of the Korean Surgical Society 1992;43(6):794-801
No abstract available.
5.Consecutive Esotropia Following Surgery for Intermittent Exotropia.
Journal of the Korean Ophthalmological Society 1999;40(12):3491-3496
Authors reviewed 459 cases which had been followed up over 3 months after surgery to evaluate the incidence of consecutive esotropia and its associated factors. For every case, we investigated the age at the surgery, the methods of surgery, stereopsis, cycloplegic refractive power, the deviation difference between far and near fixation, the deviation before surgery and the results at the postoperative 1 day, 1 week, 1 month, 4 months, 6 months, 1 year and 3 years. The incidence of consecutive esotropia tended to decrease as time passed, and occurred in 21 cases[4.6%] at the last follow-up[averaging 13.1 months]. When the deviation difference between at the distance and the near fixation was above 10 delta and the results at the postoperative 1 day was overcorrection above 10 delta, with significantly higher[p<0.05] incidence of consecutive esotropia. Other factors were not statistically significant. In conclusion, the preoperative factor was the far and near deviation difference above 10 delta and the postoperative factor was the first day postoperative overcorrection above 10 delta. It is considered that the nonsurgical treatment can be desirable for the former cases, and overcorrection above 10 delta should be avoided for the latter.
Depth Perception
;
Esotropia*
;
Exotropia*
;
Incidence
7.Family dynamics of juvenile sex violence.
Journal of Korean Neuropsychiatric Association 1992;31(3):604-628
8.A Clinical analysis of the Tibial Piateau Fracture
Chang Soo KANG ; Byung Woo MIN
The Journal of the Korean Orthopaedic Association 1988;23(3):733-742
The tibial plateau fracture which involving articular surface of the proximsl tibia is very common in pedestrian injury of the traffic accident and sometimes results in significant disability in knee joint function. The authors analized 40 cases of the tibial plateau fracture treated in our depsrtment during the year 1980 through 1985. The results obtained are as follows : l. 15 cases were treated by conservative methods. 2. 25 cases were treted by operative methods. 3. 33 cases(82.5%) were “Acceptable” group according to Roberts criteria.
Accidents, Traffic
;
Knee Joint
;
Tibia
9.Antidepressant and the Quality of Life of Depressive Patient.
Journal of the Korean Society of Biological Psychiatry 1997;4(1):116-120
This study investigated the antidepressant efficacy and it's impact on the quality of life of depressed patients. We performed Hamilton Depression Rating Scale(HDRS), and Montgomery-Asberg Depression Rating Scale(MADRS), and Health-related Quality of Life Questionnaire(HQLQ) to both tricyclic antidepressant(TCA) and sertraline groups. There were 16 subjects in the study. The tricyclic group had 9 subjects and the sertraline group had 7. The TCA and sertraline produced a similar degree of response. Both groups experienced a reduction of 70% or more in mean HDRS and MADRS total score after 6wks. In HQLQ, the TCAs group also showed improved bed disability days, alertness behavior, and social interaction, the sertraline group showed improved health perception, alertness behavior, home management, and social interaction. We suggested that the improvement of "Quality of life" were not in proportion to the clinical symptom's improvement. Therefore, clinicians should consider the benefit of antidepressant treatment in terms of quality of life.
Depression
;
Humans
;
Interpersonal Relations
;
Quality of Life*
;
Sertraline
10.Pharmacogenomics of Depressive Disorders.
Journal of the Korean Society of Biological Psychiatry 2001;8(2):226-232
The phamacotherapy of depression has reduced morbidity and improved outcome for many depressive patients. A wide range of classical and new antidepressants are available for their treatment. However, 30-40% of all patients do not respond sufficiently to the initial treatment and present adverse effects. Pharmacogenetics studies the genetic basis of an individual's ability to respond to pharmacotherapy. Recently, some reports on serotonin transporter gene polymorphisms and their influence on the response to antidepressive therapy provide an interesting diagnostic tool in assessing the chances of response to antidepressants. We also investigated the relationship between serotonin transprter polymorphisms(5-HTTLPR) and the long-term effect of the antidepressant treatment. 128 depressive patients were enrolled into 2nd year study. The therapeutic response of each subset was not different at 8th, 16th week. but the subset with homozygote(l/l) of long variant showed a better therapeutic response to antidepressant than the heterozygote(l/s) of long and short variant, which showed a better therapeutic response than the subset with homozygote(s/s) of short variant at 1st year and 2nd year after the antidepressant treatment. This result shows that the serotonin transporter polymorphisms may be related to the long-term effect of antidepressant treatment. The potential for pharmacogenomics. the use of genetic increasing attention pharmacogenomics will contribute to individualize drug choice by using genotype to predict positive clinical outcomes, adverse reactions, and levels of drug metabolism. Personalized medicine the use of marker-assisted diagnosis and targeted therapies derived from an individual molecular profile, will impact the antidepressant therapy and this approach will replace the traditional trial-and-error practice of medicine.
Antidepressive Agents
;
Depression
;
Depressive Disorder*
;
Diagnosis
;
Drug Therapy
;
Genotype
;
Humans
;
Precision Medicine
;
Metabolism
;
Pharmacogenetics*
;
Serotonin
;
Serotonin Plasma Membrane Transport Proteins